| Source: HalifaxProj (inhibit) CGL-Driver Genes |
| Type: Antiapoptotic Oncogene |
| The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID. Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells. |
| 1839- | VitK3, | Vitamin K3 derivative inhibits androgen receptor signaling in targeting aggressive prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| - | in-vitro, | Oral, | NA | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | HaCaT |
| 7919- | VT, | Apoptosis triggered by vitexin in U937 human leukemia cells via a mitochondrial signaling pathway |
| - | in-vitro, | AML, | U937 |
| 7916- | VT, | Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway |
| - | in-vitro, | HCC, | NA |
| 4886- | ZER, | Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio |
| - | in-vitro, | Liver, | HepG2 |
| 9131- | ZYF, | Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets |
| - | vitro+vivo, | PC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:27 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid